We are using cookies in order to facilitate your navigation on this website. You can read about how we use cookies and how to manage them here. By continuing to navigate on this website or clicking on the button, you accept our cookie notice and related Privacy Policy.
I accept the use of cookies
Molecular Partners
  • Partnering
  • Careers
  • Contact Us
  • About Us
  • Our DARPin® Platform
  • Our Approach
  • Pipeline
  • Investors
    • Share Information
    • Analyst Coverage
    • News Releases
    • Investor & Scientific Documents
    • General Meetings
    • Governance & Compliance
    • Financial Calendar & Events
    • Investor Contact
    • Register for Email News
  • News
  • Home
  • About Us
  • Our DARPin® Platform
  • Our Approach
  • Pipeline
  • Investors
      « Back
    • Investors
    • Share Information
    • Analyst Coverage
    • News Releases
    • Investor & Scientific Documents
    • General Meetings
    • Governance & Compliance
    • Financial Calendar & Events
    • Investor Contact
    • Register for Email News
  • News
  • Partnering
  • Careers
  • Contact Us

In the News

In the News

<< Back

2019

May 2019

Taking a Drug to Market “Is a Marathon, Not a Sprint”

2018

July 2018

Allergan and Molecular Partners release positive Phase III data on AMD drug

July 2018

In two PhIII wins for Allergan/Molecular Partners, wet AMD drug shows non-inferiority to Lucentis

July 2018

Allergan, Molecular Partners eye drug meets main goal in two studies

April 2018

AstraZeneca deal shows promise for Molecular Partners’ lung cancer therapy

April 2018

Molecular Partners gets AZ support for lung cancer trial

February 2018

Allergan exercises third option for Molecule Partners’ DARPin products

2017

October 2017

DARPins: an eye-opening new biologic therapy

2015

July 2015

Allergan goes full speed ahead with Molecular Partners’ Darpin AMD program

  • Cookie Notice
  • Privacy & Disclaimer
  • Contact Us

© 2021 Molecular Partners.